{
    "clinical_study": {
        "@rank": "63945", 
        "arm_group": {
            "arm_group_label": "Afatinib plus Ruxolitinib combination (single arm)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This phase Ib study will investigate dose limiting toxicity (DLT) and maximum tolerated dose\n      (MTD) of afatinib and ruxolitinib combination therapy, based on the preclinical data that\n      inhibition of IL-6R/JAK1 signal transmission pathway will increase sensitivity to afatinib."
        }, 
        "brief_title": "Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Stage 4 NSCLC patients\n\n          2. disease progression after platinum doublet (all), EGFR TKI (if EGFR mutant), and\n             crizotinib (if ALK positive)\n\n          3. Men and women aged 20 years or older\n\n          4. Recovery from previous drug-related toxicity: CTCAE 4.03 \u2264 Grade 1\n\n          5. ECOG 0 or 1\n\n          6. able to orally take and retain drug\n\n          7. have a measurable or unmeasurable lesion under RECIST 1.1 Criteria\n\n          8. have proper hematological, renal, and hepatic functions\n\n          9. intention to use an acceptable contraception\n\n         10. able to read and understand the informed consent form\n\n        Exclusion Criteria:\n\n          1. previous chemotherapy, radiation therapy, immunotherapy, or other anticancer therapy\n             within 14 days\n\n          2. Clinically significant gastrointestinal disorder or malabsorption syndrome\n\n          3. Acute digestive disorder\n\n          4. major organ failure\n\n          5. Significant cardiac disorders\n\n          6. major operation of a main organ in 4 weeks\n\n          7. Untreated symptomatic brain metastasis\n\n          8. pregnant or nursing\n\n          9. previously diagnosed Interstitial lung disease(ILD)\n\n         10. previously treated with irreversible pan-HER inhibitor including Afatinib or\n             Ruxolitinib\n\n         11. previously experienced hypersensitivity to an ingredient of the study drug\n\n         12. must receive CYP3A4 inducer or inhibitor persistently during the study period.\n\n         13. HIV positive or active hepatitis\n\n         14. threatening patient's safety is predicted"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145637", 
            "org_study_id": "4-2013-0405"
        }, 
        "intervention": {
            "arm_group_label": "Afatinib plus Ruxolitinib combination (single arm)", 
            "intervention_name": "Afatinib plus Ruxolitinib combination therapy", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Cancer, Lung cancer, Head and neck squamous cell carcinoma, Afatinib, Ruxolitinib, EGFR, JAK, STAT", 
        "lastchanged_date": "May 27, 2014", 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "cbc1971@yuhs.ac", 
            "last_name": "Byung Chul Cho, MD, PhD", 
            "phone": "82-10-5212-8867"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will set a recommended phase II dose (RP2D) using conventional 3+3 deisgn.", 
            "measure": "To set a recommended phase II dose (RP2D)", 
            "safety_issue": "Yes", 
            "time_frame": "36 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events (AEs) will be assessed according to NCI common toxicity criteria (CTC) version 4.03.", 
                "measure": "Safety and tolerability (dose relating toxicity; DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "1year"
            }, 
            {
                "description": "Response and progression will be evaluated in this study using modified international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "1year"
            }, 
            {
                "description": "PFS will be defined as the start of the treatment to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1year"
            }, 
            {
                "description": "OS will be defined as the start of the treatment to the date of death due to any cause.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "1year"
            }, 
            {
                "description": "The biomarkers marker related with EGFR and JAK/STAT pathway as well as gene analysis, using peripheral blood mononuclear cell(PBMC), circulating tumor cell (CTC) and skin and tumor tissue sample will be analyzed.", 
                "measure": "Pharmacodynamic biomarker", 
                "safety_issue": "No", 
                "time_frame": "1year"
            }
        ], 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}